Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 19, 2019Oral Presentation about Results from First Phase 3 Head-to-Head Study with Pre-specified Endpoints vs. Zolpidem ER (SUNRISE 1)
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that new long-term, Phase 3 data and additional analyses of lemborexant will be highlighted in eight...
-
Sep 13, 2019Discontinuation of studies based on Data Safety Monitoring Board recommendation
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Jul 11, 2019
In the news release, New Data in 2 Oral and 13 Poster Presentations about Eisai's Latest Dementia Pipeline, Including BAN2401, Elenbecestat and Lemborexant, to be Presented at Alzheimer's...
-
Jul 9, 2019New Research Center Focused on Immunotherapy for Dementia
Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., announced today the opening of its Eisai Center for Genetics Guided Dementia Discovery ("G2D2"), a new exploratory research facility located in...
-
Jun 25, 2019- Results of the FREEDOM Study (Study 342) presented at the 33rd International Epilepsy Congress (IEC)
Eisai Inc. today announced results from its FREEDOM Study (Study 342), a Phase III open-label study conducted in Japan and South Korea evaluating the efficacy and safety of FYCOMPA® (perampanel)...